Kurtoglu Metin 的 Form 4 申報
Cartesian Therapeutics, Inc.（RNAC），2024/11/18 申報
- 申報編號
- 0001453687-24-000132
- 申報時間
- 2024/11/18
- 交易日
- 2024/11/14-11/18
- 申報延遲
- 4 天
- 10b5-1 計畫
- 沒有勾選
這份申報列了 8 筆非衍生性交易、3 筆衍生性交易。公開市場賣出合計 $143.8 萬。交易後 4 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Kurtoglu MetinCIK 0002000284 | 高階主管（技術長） |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2024/11/14 | Common Stock | M行使選擇權取得 | +25,900 | $1.41 | +$36,519 | 76,933 | 直接 | |
| 2024/11/14 | Common Stock | S賣出處分 | −21,900 | $16.33F1 | −$357,627 | 55,033 | 直接 | |
| 2024/11/14 | Common Stock | S賣出處分 | −4,000 | $17.06F2 | −$68,240 | 51,033 | 直接 | |
| 2024/11/15 | Common Stock | M行使選擇權取得 | +22,068 | $1.41 | +$31,115.88 | 73,101 | 直接 | |
| 2024/11/15 | Common Stock | S賣出處分 | −22,068 | $17.20F3 | −$379,569.6 | 51,033 | 直接 | |
| 2024/11/18 | Common Stock | M行使選擇權取得 | +34,400 | $1.41 | +$48,504 | 85,433 | 直接 | |
| 2024/11/18 | Common Stock | S賣出處分 | −16,672 | $18.19F4 | −$303,263.68 | 68,761 | 直接 | |
| 2024/11/18 | Common Stock | S賣出處分 | −17,728 | $18.58F5 | −$329,386.24 | 51,033 | 直接 |
衍生性證券（表 II）
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $16.00 to $16.65. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F2
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $17.00 to $17.12. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F3
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $17.00 to $17.42. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F4
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $17.50 to $18.49. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F5
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $18.50 to $18.69. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F7
On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series A Preferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock.
表 II 有 3 筆交易的價格引用這則附註。